NCT07509528Completed
Sarcopenia Predictors in Patients With COPD
Examination of Factors Affecting Sarcopenia in Patients With COPD
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
Chronic obstructive pulmonary disease (COPD) is a significant, preventable, and treatable public health problem and a growing cause of chronic morbidity and mortality worldwide. Frailty is a biological syndrome resulting from a progressive decrease in the reserve capacity of multiple physiological systems. COPD and frailty are closely associated with common risk factors such as aging, tobacco use, impaired neuroendocrine function, immune system dysfunction, and chronic inflammation. Cardiopulmonary exercise testing (CPET) is a valuable tool for assessing exercise capacity, evaluating the severity of limitations, and identifying their causes. CPET provides an objective measurement of exercise capacity with direct applications in risk stratification. It also guides rehabilitation practices, including the planning and prescription of exercise training. COPD is associated with a systemic inflammatory process that can lead to progressive loss of muscle mass and function and sarcopenia. The prevalence of COPD in sarcopenic patients varies between 4.4% and 86.55% due to the variability of various diagnostic tools, different reference values, and threshold values presented in the literature Further research is needed in the literature regarding the role of sarcopenia and factors that may affect sarcopenia, such as cardiorespiratory exercise capacity, in a specific lung disease like COPD. The primary aim of this study was to examine the differences in respiratory function, respiratory muscle strength, cardiopulmonary exercise capacity, rectus femoris muscle thickness, activities of daily living, balance, and frailty parameters among patients with possible sarcopenic, sarcopenic, and severe sarcopenic COPD. The secondary aim of this study was to identify the factors affecting sarcopenia in COPD patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 42 (actual)
- First submitted
- 29 Mar 2026
- Start date
- Jun 2024
- Primary completion date
- May 2025
- Lead sponsor
- Hacettepe University
- Diseases
- COPD
- NCT number
- NCT07509528
What you commit to
- Study type: Observational
- Participants enrolled: 42
- From Jun 2024 to the primary completion date, May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individuals with any additional neuromuscular, musculoskeletal, cardiac, rheumatological, neurological, psychiatric or orthopedic disease,
- other chronic diseases that may affect balance and walking,
- cognitive impairment (Mini Mental Test score \<24) (13) were not included in the study.
Who the study is looking for
- Individuals who were clinically stable for the past month and not using antibiotics,
- 40 years of age and older, cooperative, able to ambulate without support or assistive devices,
- diagnosed with and followed up at the Chest Diseases Outpatient Clinic of Bursa City Hospital,
- evaluated for sarcopenia by an internal medicine and geriatrics specialist,
- and volunteered to participate in the study were included.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bursa City Hospital Coordinator of this site? Confirm its status | Bursa | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.